CCR4 and neoplasm: Simultaneous administration of an anti-PD-1 antibody, nivolumab, with a Treg-depleting anti-CCR4 mAb, mogamulizumab, provides an acceptable safety profile, anti-tumour activity, and a potentially effective option in cancer immunotherapy [494].